Anti-CXCR4 antibodies and antibody-drug conjugates
AssigneePfizer Inc.
InventorsShu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
Claims3
An isolated polynucleotide comprising a nucleotide sequence encoding an antibody, or an antigen binding fragment thereof, that binds to chemokine receptor 4 (CXCR4) and comprises:
- a) a heavy chain variable (VH) CDR1 comprising the amino acid sequence shown in SEQ ID NO:
- 107, 108, 109, 113 or 114;
- a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO:
- 110 or 111;
- and a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO:
- 112;
- and;
- b) a light chain variable region (VL) CDR1 comprising SEQ ID NO:
- 131;
- a VL CDR2 comprising 132;
- and a VL CDR3 comprising SEQ ID NO:
- 133.
Dependencies are inferred from the claim text.